Aller au contenu principal
Retour à l'annuaire
RhumatologueMédecins généralistes et spécialistes👤 Libéral intégral

M. Docteur Michel FRANCO

📍 Nice (06)Libéral💶 Secteur 1RPPS 10003285714
📊 Reconnaissance scientifique : 31/100📝 54 articles publiés📚 HAL (8)

✨ Profil synthétique

IA · 29/04/2026

Le Docteur Michel FRANCO est un rhumatologue libéral exerçant à Nice, avec une activité de recherche significative. Son h-index est de 31, avec 54 publications, principalement axées sur des thématiques biomoléculaires et cellulaires. Ses publications sur PubMed couvrent divers aspects de la rhumatologie, notamment l'épidémiologie, les traitements et la rééducation.

Expertises présumées

  • Polyarthrite rhumatoïde
  • Spondylarthrite ankylosante
  • Thérapies biologiques
  • csDMARDs
  • Rééducation fonctionnelle
  • Activité physique adaptée
  • Évaluation économique des traitements

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

Diplômes

🎓 DES & spécialité ordinale

  • Rhumatologie (SM)

📚 CES (Certificat d'Études Spéciales)

  • CES Rhumatologie

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

31

h articles cités ≥ h fois chacun. Un h de 31 = 31 publications avec 31+ citations.

Citations

2 966

Publications

54

i10-index

42

Thématiques principales

  • Cellular transport and secretion ×31
  • Protein Kinase Regulation and GTPase Signaling ×11
  • Receptor Mechanisms and Signaling ×9
  • Lipid Membrane Structure and Behavior ×8
  • Ion channel regulation and function ×6

Affiliations FR : Centre National de la Recherche Scientifique · Université Côte d'Azur · Institut de Pharmacologie Moléculaire et Cellulaire

Voir sur OpenAlex ↗🆔 ORCID 0000-0003-1853-8661

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

Tarifs & secteur de conventionnement

🟢 Secteur 1 — Tarif conventionnéSource CNAM (Annuaire santé Ameli)
💳 Carte VitaleLibéral intégral
📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Vidéos & interventions (1)

Source YouTube · recherche par nom (homonymes possibles).

Top publications · les plus citées

  • 1
    Pain Biomarkers in Fibromyalgia Syndrome: Current Understanding and Future Directions

    International journal of molecular sciences · 2023

    📚 37 citations🎯 RCR 7.93Top 4% NIH🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Fibromyalgia is a complex and heterogeneous clinical syndrome, mainly characterized by the presence of widespread pain, possibly associated with a variety of other symptoms. Fibromyalgia can have an extremely negative impact on the psychological, physical and social lives of people affected, sometimes causing patients to experience dramatically impaired quality of life. Nowadays, the diagnosis of fibromyalgia is still clinical, thus favoring diagnostic uncertainties and making its clear identification challenging to establish, especially in primary care centers. These difficulties lead patients to undergo innumerable clinical visits, investigations and specialist consultations, thus increasing their stress, frustration and even dissatisfaction. Unfortunately, research over the last 25 years regarding a specific biomarker for the diagnosis of fibromyalgia has been fruitless. The discovery of a reliable biomarker for fibromyalgia syndrome would be a critical step towards the early identification of this condition, not only reducing patient healthcare utilization and diagnostic test execution but also providing early intervention with guideline-based treatments. This narrative article reviews different metabolite alterations proposed as possible biomarkers for fibromyalgia, focusing on their associations with clinical evidence of pain, and highlights some new, promising areas of research in this context. Nevertheless, none of the analyzed metabolites emerge as sufficiently reliable to be validated as a diagnostic biomarker. Given the complexity of this syndrome, in the future, a panel of biomarkers, including subtype-specific biomarkers, could be considered as an interesting alternative research area.

  • 2
    Fibromyalgia: one year in review 2023

    Clinical and experimental rheumatology · 2023

    📚 31 citations🎯 RCR 8.24Top 3% NIH🔓 Open Access📄 PDF gratuit ↗
  • 3
    Gut Microbiota Structure and Metabolites, Before and After Treatment in Early Rheumatoid Arthritis Patients: A Pilot Study

    Frontiers in medicine · 2022

    📚 29 citations🎯 RCR 2.84Top 17% NIH🔓 Open Access
    Lire l'abstract Crossref ↓

    Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease. Modifications of gut microbiota seem to be associated with the disease, but the impact of gut microbiota on therapies’ outcome remains unclear. A role of T cells in RA pathogenesis has been addressed, particularly on the Th17/Treg cells balance. Our study aimed to evaluate in early RA (ERA) patients compared to a control group, fecal gut microbiota composition, short-chain fatty acids concentrations, and the levels of circulating Th17/Treg and their own cytokines, before and after 3 months of standard treatment (Methotrexate (MTX) plus glucocorticoids). Fecal microbiota characterization was carried out on 19 ERA patients and 20 controls matched for sex and age. Significant decreased biodiversity levels, and a partition on the base of the microbiota composition, between the ERA patients at baseline compared to controls, were observed. The co-occurrent analysis of interactions revealed a characteristic clustered structure of the microbial network in controls that is lost in ERA patients where an altered connection between microbes and clinical parameters/metabolites has been reported. Microbial markers such as Acetanaerobacterium elongatum, Cristiansella massiliensis, and Gracilibacter thermotolerans resulted significantly enriched in control group while the species Blautia gnavus emerged to be more abundant in ERA patients. Our results showed an alteration in Th17/Treg balance with higher Th17 levels and lower Treg levels in ERA group respect to control at baseline, those data improved after therapy. Treatment administration and the achievement of a low disease activity/remission appear to exert a positive pressure on the structure of intestinal microbiota with the consequent restoration of biodiversity, of the structure of microbial network, and of the abundance of taxa that became closer to those presented by the subject without the disease. We also found an association between Blautia gnavus and ERA patients characterized by a significant reduction of propionic acid level. Furthermore significant differences highlighted at baseline among controls and ERA patients are no more evident after treatment. These data corroborate the role played by gut microbiota in the disease and suggest that therapy aimed to restore gut microbiota would improve treatment outcome.

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal28

▼

Revue générale5

▼

Épidémiologie & registres4

▼

csDMARDs2

▼

Économie santé2

▼

Activité physique / Rééducation1

▼

Anti-TNF1

▼

Biomarqueurs / Auto-Ac1

▼

Biothérapies non-anti-TNF1

▼

Génétique1

▼

Lombalgie1

▼

Lupus1

▼

Microbiote1

▼

Revue / méta-analyse1

▼

Sjögren1

▼

Datasets & protocoles partagés

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.